z-logo
open-access-imgOpen Access
EXPERIENCE OF NIFURATEL USAGE IN COMPLEX TREATMENT OF CHRONIC SPECIFIC BACTERIAL FIBROUSE AND CALCULOUS PROSTATITIS ASSOCIATED WITH TRICHOMONIASIS AND CANDIDOSIS
Author(s) -
Юрий Заседа
Publication year - 2018
Publication title -
mužskoe zdorovʹe, gendernaâ i psihosomatičeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2414-4339
pISSN - 2413-8843
DOI - 10.37321/ujmh.2018.01-02
Subject(s) - prostatitis , medicine , chronic bacterial prostatitis , trichomoniasis , prostate , gynecology , cancer
The aim of the study was to analyze the effi cacy of the drug “Macmiror” (active substance – nifuratel) in the treatment of chronic specifi c bacterial fi brous and calculous prostatitis associated with trichomoniasis and candidiasis.Materials and methods. The study was conducted on 50 patients of the “Clinic “Men’s Health”, suff ering from chronic specifi c bacterial fi brous and calculous prostatitis (mixed infection: trichomonadial-bacterial-candidiasis associates of various structure). As methods of research, in addition to the standard complex, the following were chosen: IN POUCH TV-test; PCR method; sonographic examination ofthe prostate and spermogram.Results of the study. Patients who completed the study were treated with chronic specifi c bacterial fi brous and calculous prostatitis (N41.1) for 14 days, according to the following therapeutic model: oral administration of nifuratel as part of the “Macmiror” preparation at a total dosage of 1200 mg per day (6 tablets of 200 mg) divided into 3 doses and physiotherapy.Conclusions. A general (in relation to diff erent types and combinations of infectious agents) of the therapeutic model has been established at a level of 71% to 100%. Treatment had absolute (clinical and laboratory) effi cacy against isolated Candida spp.; absolute clinical effi cacy and 71-85% laboratory effi cacy against isolated Trichomonas vaginalis; 92% clinical and 76-84% laboratory effi cacy against the combination of these infectious agents; 92% clinical and 80% laboratory effi cacy against the combination of these infectious agents and non-specifi c bacterial fl ora, as the etiological factors of chronic specifi c bacterial prostatitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here